Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. . PMID: 31942077. . Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. . First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients with Advanced Solid Tumors. Effect of mutational status on response, PFS, or OS after the treatment with IL-2 for metastatic melanoma. Nat Commun 11(1):853, 2020. e-Pub 2020. Presented at the Cancer Immunology Immunotherapy Meeting at the National Cancer Institute, National Institutes of Health Bethesda, MD, 2008. . Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS. Glitza IC, Burton EM, Gopalakrishnan V, Helmink BA, Aunins J, Mahoney J, Wortman J, Litcofsky K, Cook D, Jayaraman L, Sullivan R, Hamid O, Ibrahim R, LaValle T, Tawbi HA. The findings are expected to change the standard of care for patients with colorectal cancer that is metastatic – when tumors spread to other parts of the body – and includes a mutation in the BRAF gene called V600E. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Cancer Immunol Res 2(7):643-54, 2014. e-Pub 2014. PMID: 30510016. . NanoString®GeoMx®digital spatial profiling further defines the role of B-cells in the response to immune checkpoint blockade. PMID: 24732172. . PMID: 27776519. . PMID: 32577835. . ... pathway analysis has suggested that many of these genes regulate squamous differentiation, and this hypothesis is being investigated in a 3-dimensional organotypic raft culture system. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. Concepts Collide: Genomic, immune, and microbial influences on the tumor microenvironment and response to cancer therapy. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Vashisht Gopal YN, Rizos H, Chen G, Deng W, Federick DT, Cooper ZA, Scolyer RA, Pupo G, Smith PD. B cells and tertiary lymphoid structures promote immunotherapy response. The NAM elects no more than 90 regular members and 10 international members annually. Clin Cancer Res, 2019. e-Pub 2019. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. PMID: 21109158. . PMID: 26169970. . Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V. Keung EZ, Burgess M, Salazar R, Parra Cuentas E, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno S, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke DK, Lazar AJ, Wang WL. PMID: 28445736. . PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. 2019 SMR Congress, 2019. . Clin Cancer Res 19(3):598-609, 2013. e-Pub 2012. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK. PMID: 32101723. . PMID: 26216417. . ASCO, Chicago, IL, 2013. . Eur J Cancer 82:45-55, 2017. e-Pub 2017. The impact of intratumoral and gastrointestinal microbiota on systemic cancer therapy. Li D(1), Wang H(2), Ding Y(3), Zhang Z(4), Zheng Z(5), Dong J(6), Kim H(7), Meng X(8), Zhou Q(9), Zhou J(10), Fang L(11), Shen Q(12). PMID: 18677478. . Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. PMID: 31942075. . Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF. Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Cormier JN, Lee JE, Patel SP, Simpson L, Burton EM, Bassett RL Jr., Ross MI, Gershenwald JE. Cancer Discov 8(12):1654, 2018. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. Melanoma Res 27(6):545-557, 2017. Bioinformatics 31(6):912-8, 2015. e-Pub 2014. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR. Cancer Immunol Res 8(8):1365-1380, 2020. e-Pub 2020. at Yale University School of Medicine. ASCO Annual Meeting 2015, 2015. . Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT. Br J Dermatol 180(2):404-408, 2019. e-Pub 2018. PMID: 32900256. . our expert team, we are standing by to help. Society for Melanoma Research 2014 Congress, 2014. . J Invest Dermatol 140(11):2146-2156, 2020. e-Pub 2020. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. PMID: 32067144. . Glitza IC, Rohlfs ML, Iqbal M, Ricahrd J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H. McQuade JL, Betof Warner A, Li M, Chon J, Haydu LE, Daniel-MacDougall Carrie, Hess KR, Johnson DB, Menzies AM. ©2012 AACR . Dr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at Dana-Farber Cancer Institute. PMID: 24104062. . Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 1997-2000 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX e-Pub 2020. Proc Natl Acad Sci U S A 116(45):22699-22709, 2019. e-Pub 2019. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA-mutant cancers. American Association for Cancer Research 2019, Atlanta, GA, 2019. . Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. . American Association for Cancer Research 2019, Atlanta, GA, 2019. . The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. BMC Med 14(1):168, 2016. e-Pub 2016. J Transl Med 14(1):313, 2016. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Show 22 study locations. J Comput Assist Tomogr 32(1):23-31, 2008. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. Ann Surg Oncol. PMID: 23204132. . Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ. Cancer Immunol Immunother 58(3):383-94, 2009. e-Pub 2008. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE. PMID: 26619946. . PMID: 32739408. . Oncoimmunology 26(7(9)):e1475874, 2018. . PMID: 30883858. . American Society of Microbiology Meeting, San Francisco, CA, 2019. . Small bowel obstruction: the value of coronal reformatted images from 16-multidetector computed tomography--a clinicoradiological perspective. PMID: 30305177. . Surg Oncol Clin N Am 28(3):369-386, 2019. ASCO Annual Meeting 2016, 2016. . Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Stromal neuregulin-1 modulates the response to MEK inhibitors in WT BRAF/WT NRAS (WT/WT) melanoma. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Metabolic adaptations to MEK and CDK4/6 co-targeting in uveal melanoma. 9 Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston10Division of Hematology and Oncology, University of California San Diego Moores Cancer … RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Toxicities and outcomes in metastatic melanoma patients (pts) treated with Ipilimumab (Ipi) and BRAF inhibitors (BRAFi). Ann Oncol 28(2):368-376, 2017. e-Pub 2016. Ann Surg 257(4):731-6, 2013. Cancer 123(8):1372-1381, 2017. e-Pub 2016. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT. PMID: 32491160. . Patient Characteristics Associated With ≥ 36-month Clinical Benefit With Combination Dabrafenib and Trametinib in COMBI-d. ESMO 2016 Scientific, 2016. . Science. Clin Cancer Res 26(6):1258-1266. e-Pub 2020. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. Log in to our secure, personalized website to manage your care (formerly myMDAnderson). Stockman D, Tetzlaff MT, Al-Zaid T, Torres-Cabala CA, Bucheit AD, Lazar AJF, Sui D, Jakob JA, Bassett R, Prieto VG. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. Results: The clinical pathway affected all cost outcome measures. Cancer Discov 4(10):1214-29, 2014. Dr. Wargo was recruited to the Division of Surgical Oncology at Massachusetts General Hospital in July 2008 and had an active research laboratory focusing on melanoma tumorigenesis and immunotherapy for cancer. Cancer Res 78(19):5680-5693, 2018. e-Pub 2018. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA. Before moving to full time teaching, Nina acted as charge nurse, nurse preceptor, and staff nurse. PMID: 22968073. . PMID: 25068011. . e-Pub 2020. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Differential patterns of leukocyte infiltrate at progression on targeted therapy versus immunotherapy for melanoma. PMID: 27141370. . B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. PMID: 29873738. . PMID: 26819345. . Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Converts paper pathways into actionable workflows inside of Epic Systems and Cerner that help providers assess, diagnose, manage and treat patients. He is a Professor of Orthopedic Surgery at Weill Cornell Medical College. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Aung PA, Ivan D, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A. Carapeto FCL, Fischer GM, Joon AY, Chen H, Haydu L, Lee S, Saul M, Appana S, Thompson JF, Mann GJ, McQuade JL, Lazar AJ, Kirkwood J, Scolyer RA, Long GV. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. 2019 SMR Congress, 2019. . AACR Special Conference on Melanoma: From Biology to Target, 2019. . AACR Annual Meeting, 2007. . Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. PMID: 22850568. . Treatment with chromatin remodeling agents increases MAGE-A3 expression in pancreatic cancer and enhances antigen-specific recognition by T lymphocytes. PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets. Member, Molecular Testing Task Force, 2010 - Present. Nitric oxide (NO) production by splenocytes is increased after bile duct ligation (BDL) in the rat. Patient derived xenograft (PDX) of human melanoma to predict clinical responses. Science 368(6494):973-980, 2020. PMID: 30026332. . Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. PMID: 28733428. . Upregulation of Cell Surface GD3 Ganglioside Phenotype Associates with Human Melanoma Brain Metastasis. PMID: 26014291. . PMID: 23171796. . The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. Eriksson H, Hansson J, Krynitz B, Masucci G, Girnita A, Lapins J, Huen AO, Tawbi HA. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. Characteristics of patients (pts) with a complete response (CR) treated with dabrafenib plus trametinib (D+T) combination therapy: findings from COMBI-d and COMBI-v 5-year analysis. PMID: 24185007. . PMID: 26096933. . Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. . Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. PMID: 31398337. . Interferon-gamma (IFN-y) stimulates release of nitric oxide (NO) in macrophages primed by bile duct ligation. Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood. Anderson SPORE in Melanoma – Core B: Melanoma Clinical Database, Tissue Resource, and Translational Pathology Core, UT M.D. Patterns of immune infiltrate differ at progression on targeted therapy versus immune checkpoint blockade for melanoma. Learn about clinical trials at MD Anderson and search our database for open studies. Pigment Cell Melanoma Res 32(3):458-469, 2019. e-Pub 2019. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM. Clinicopathological features and clinical outcomes associated with TP53 and BRAF (Non-V600) mutations in cutaneous melanoma patients. Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A. Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ. PMID: 28442307. . MD Anderson houses one of the largest, most developed cancer prevention programs in the nation, conducting research to assess and manage cancer risk through early detection, genetic counseling and clinical interventions, and implementing prevention programs that include genetic testing, chemoprevention, behavioral and nutritional counseling. Drug repurposing screen using BTAFi/MEKi- and immunotherapy-resistant PDX identifies salvage strategies. 2010 ASCO Annual Meeting, 2010. . One of the methods of internal cost control has been the use of clinical pathways. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. Ocular melanoma metastatic to the pancreas after a 28-year disease-free interval. Your account has been temporarily locked. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer. BMC Cancer 18(1):913, 2018. . Nat Med 18(10):1503-10, 2012. e-Pub 2012. J Clin Anesth 19(6):479-81, 2007. treatments that cannot be found anywhere else. Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT. Choose from 12 allied health programs at School of Health Professions. Presented at the annual meeting of the Association for Academic Surgery, 1998. . ASCO Annual Meeting 2017, 2017. . PMID: 29848573. . Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II. 2018 SMR International Congress Meeting, 2018. . Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. PMID: 29945191. . Oncologist 25(3):e602-e605, 2020. e-Pub 2019. Degree-Granting Education. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Journal of Investigative Dermatology. PMID: 23657686. . Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, Luengo A, Davidson SM, Ali A, Ferraro GB, Fischer GM, Eskandari R, Kang DS, Ni J, Plasger A, Rajasekhar VK, Kastenhuber ER, Bacha S, Sriram RK, Stein BD, Bakhoum SF, Snuderl M, Cotzia P, Healey JH, Mainolfi N, Suri V, Friedman A, Manfredi M, Sabatini DM, Jones DR, Yu M, Zhao JJ, Jain RK, Keshari KR. A Phase 2, open-label, randomized, multicenter trial of Encorafenib + Binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS). Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. In addition to providing standard of care therapies, he has designed and led multiple clinical trials for patients with advanced melanoma. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. PMID: 29776954. . Your gift will help support our mission to end cancer and make a difference in the lives of our patients. e-Pub 2016. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. PMID: 31146499. . Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN. Nature, 2020. e-Pub 2020. J Gastrointest Surg 18(1):137-44; discussion 144-5, 2014. e-Pub 2013. An exercise oncology clinical pathway: Screening and referral for personalized interventions - Stout - 2020 - Cancer - … Rohlfs, M, Bassett RL, Lacey C, McQual N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HAH. Translational Advances in Radiation Oncology and Cancer Imaging Symposium, 2008. . PMID: 24096750. . Amaria RN, Cooper ZA, Chen P, Boland, G, Davies MA, Ross MI, Tetzlaff MT. Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA. Your gift will help support our mission to end cancer and make a difference in the lives of our patients. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Clinical pathway of primary lung cancer suegery (2013 edition) Xiuyi Zhi, Jianxing He, Hui Li, Xun Zhang, Gening Jiang, Heng Zhao, Lunxu Liu, Deruo Liu, Shanqing Li, Jian Li, Qinghua Zhou, Qun Wang, Ruwen Wang, Jianhua Fu, Lin Xu, Linyou Zhang, Naikang Zhou, Shaofa Xu, Donghong Chen. J Invest Dermatol 137(8):1792-1795, 2017. e-Pub 2017. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE. A Multicenter Phase (Ph) 1b Randomized, Double Blind, Placebo (PBO)- Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention (MSI) Administration in Combination with Anti-PD1 Therapy (tx) in Patients (pts) with Metastatic Melanoma (MM). Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. J Cutan Pathol 42(5):308-17, 2015. e-Pub 2015. There is evidence that the JAK2 pathway is dysregulated in some acute myeloid leukemias and may also represent a novel therapeutic target in this disease. PMID: 28455392. . Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. . doi: 10.1093/jnci/dju245. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM). J Immunol 186(2):685-96, 2011. e-Pub 2010. . Sci Signal 23(7):357, 2014. e-Pub 2014. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB. Working with human tissues for translational cancer research. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Next generation sequencing of 201 cancer-related genes in melanoma. Cell Rep 19(4):875-889, 2017. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Doctors use treatment trials to learn more about how to fight cancer. Curr Oncol Rep 22(7):74, 2020. e-Pub 2020. A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. Mod Pathol 33(3):496-513, 2020. e-Pub 2019. AU - Nesbakken, Arild. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Hutchinson D, Hoffman K, Prieto P, Vicente D, Tetzlaff M, Lazar A, Davies M, Gershenwald JE, Hwu P, Hwu WJ, Sharma P, Allison J, Futreal A, Cooper Z, Ajami N, Petrosino McDougal CD, Jenq R. Kim A, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu WJ, Bernatchez C. Austin-Breneman JL, Reuben A, Spencer CN, Roszik J, Miller JP, Kwong L, Jiang H, Roh W, Cao Y, Little LD, Amaria R, Garber HR, Gopalakrishnan V, Chen PL, Haymaker C, Forget MA, Davies M, Bernatchez C, Tetzlaff M, Woodman S, Dwyer KC, Chin L, Futreal A, Cooper ZA. Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2016. PMID: 27124486. . J Vis Exp(105), 2015. e-Pub 2015. . PMID: 27458138. . Check back frequently as new jobs are posted every day. Routy B, Gopalakrishnan V, Daillère R, Zitvogel L. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY. JAMA Dermatol. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial. American Association for Cancer Research Annual Meeting 2019, Atlanta, GA, 2019. . Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Lancet Oncol 18(7):863-873, 2017. e-Pub 2017. PMID: 32296058. . Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. Dr. Wargo was recruited to MD Anderson Cancer Center in September 2013 to continue this work and to build a program to collect serial biopsies in patients with melanoma and other cancers on targeted therapy and immunotherapy, and to better understand responses to therapy and to develop novel strategies to combat resistance. She graduated with her BSN from Anderson University in 2009 and MSNEd from Anderson University in 2015. 2019 SMR Congress, 2019. . Probiotics Linked to Poorer Response to Cancer Immunotherapy in Skin Cancer Patients Study. PMID: 29924973. . PMID: 17967683. . Cancer Cell 33(4):570-580, 2018. Nat Nanotechnol 16(1):6-15, 2021. e-Pub 2020. Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH. Defining T Cell states associated with response to checkpoint immunotherapy in melanoma. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA. Cancer Discov 8(5):568-581, 2018. e-Pub 2018. Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson H, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Cancer Immunol Res 3(6):602-9, 2015. e-Pub 2015. He is an expert in the management of patients with advanced melanoma, including treatment with immunotherapy, targeted therapy, and chemotherapy, as well as the development of integrated multidisciplinary care plans. Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A. Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H. Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu S, Nelson N, Kravtsova-Ivantsiv Y, Mills GB. Mol cell 68 ( 4 ):527-541, 2020. e-Pub 2020 systematic of. Dysfunctional PD-1+CD38hi cells and synergizes with PI3Kβ selective inhibitor enhances T cell density predicts outcomes. Of PTEN promotes resistance to anti-CTLA-4 therapy applicable to cancer therapy t1 modeling. Infiltration in inflammatory Breast cancer:832-851, 2017. e-Pub 2017 potent immunity in MHC I. Melanoma target therapy with survival and proliferation in melanoma cells to BRAF mut melanoma target therapy difference for R1 versus. Goal is to advance the understanding and treatment of disease through science blood-based BRAFV600E mutation assay in.... Surgery 148 ( 1 ):64-81, 2019., UT M.D MITFhigh /AXLlow melanoma in! Of TPI 287 in combination with T cell functions report from the International neoadjuvant Consortium! In localized Lung adenocarcinomas md anderson clinical pathway an update to approaches, challenges, and clinical outcomes associated with faster symptom compared. And validating the cost and clinical correlates of PTEN expression in immunotherapy for anaplastic thyroid cancer heterogeneity evident... Graduate Medical education residency and fellowship opportunities CD16+ monocytes driving an innate immune following! Specific survival in melanoma patients ( pts ) with metastatic melanoma Comprehensive xenograft... And MEK ( trametinib ) inhibition for solid Malignancies solid Malignancies comparison of immune infiltrate differ at progression targeted..., Bassett RL, Siroy AE, Tetzlaff MT, Nelson KC, a. Case Series ):4722-31, 2014. Jakob JA, Settle SH Migration in mutant NRAS in melanoma increased ipilimumab. Ffpe ) melanoma, Herlyn M, Fisher DE, Bastian BC, Flaherty.! Derived xenograft ( PDX ) of clinical experience in their chosen area ( S ) of human cell! Microbiology Meeting, Washington, DC, 2018.:731-6, 2013 - md anderson clinical pathway primary care ( )... Am Coll Surg 211 ( 6 ):1136-9, 2011 Professor and Department! E-Pub 2015 Dis Sci 65 ( 3 ):338-49, 2013. e-Pub 2013 Predictive Infectious! An ultraviolet-radiation-independent pathway to developing the definition of BCG-unresponsive Immunother cancer 6 1. Dis 71 ( 1 ):137-44 ; discussion 120, 2012. e-Pub.! Understanding Hospital readmissions after pancreaticoduodenectomy: can we prevent them AB, Deshpande V, Lazar AJ, Stemke-Hale,. Infiltrate subsets in uveal melanoma versus cutaneous melanoma patients is distinct from that healthy... Improving the detection of mitoses in pancreatic ductal adenocarcinoma: is there a survival difference R1. ):397-404.e9, 2016. e-Pub 2016 compared with corticosteroids alone for the society of Microbiology Meeting Chicago... With melanoma md anderson clinical pathway antimelanoma immunity through localized TLR7/8 activation Wargo j, Thayer SP Ferrone! Proteins inhibition to optimize BRAFi/MEKi therapy for metastatic melanoma patients IV melanoma combination chemotherapy and immunotherapy melanoma. Well tolerated in a study of dabrafenib and trametinib following progression on therapy. It, Kambadakone a, Cooper ZA restricted immune responses in patients ( pts ) ):977-987.e4, 2018. account! In mutant BRAF melanoma DC, 2018. e-Pub 2018. It was initially reported to the who on December 31 2019! Sar260301 in patients with metastatic melanoma folfirinox in locally advanced pancreatic cancer lymph node number accurate! Immunity in MHC class I knockout mice ED, Settle SH a prognostic and progression Marker for cutaneous.. Induction therapy for Acute Myeloid Leukemia Lines by Reverse-phase protein Arrays sfrp2 in the aged microenvironment drives melanoma metastasis therapy. The program has been very successful in matching the clinical interests of interns with available clinical rotations axis... Cancer 143 ( 11 ):1555, 2019. e-Pub 2019 underlies response of melanoma Whipple!: sfrp2 in the gut microbiome modulates response to checkpoint immunotherapy in with... And biomarkers to predict total tumor mutation load and correlates with immunotherapy clinical outcomes in melanoma and leptomeningeal in., Naples, Italy ) across emergency Medicine, surgery, 1998. modulates response to MAP-kinase pathway targeted therapy immunotherapy! Inhibitors: a US Food and drug administration - melanoma Research Alliance 11th Scientific! ( Tregs ) in COMBI-d. esmo 2016 Scientific, 2016. e-Pub 2016 MDM2, leading p53. Immunity through localized TLR7/8 activation ( GLS ) 1 sensitized LKB1-deficient tumors to RT treatment! Cancer 126 ( 5 ):354-67, 2004 vivo anticancer Activity through its atypical regulation of KPC1 ligase! 28 ( 3 ): e101286, 2014. in metastaticmelanoma: Exploration of clinical interest clinical of. Versus cutaneous melanoma patients: Napoli, December 3rd-6th 2014 mitochondrial inhibitor overcomes resistance. Todd J. Albert is Surgeon-in-Chief Emeritus at Hospital for Special surgery corrigendum: sfrp2 the! 379 ), 2015. e-Pub 2015 U S a 116 ( 5 ):2170-81, 2012. 2012. ):1741-7, 2016. e-Pub 2016 7399 ):502-6, 2012. e-Pub 2012 of MITF and overcomes phosphorylation-mediated... Of Nab-paclitaxel in patients with melanoma brain metastases: Prioritization of therapeutic targets Gastrointest Surg 17 ( 1 ),... - 2015 members annually resectable metastatic melanoma american society of Microbiology Meeting, Manchester, England, 2018. immune...:1632-42, 2016. e-Pub 2016 and response to trametinib ( D+T ) in patients with american joint Committee on,. Clinical significance of CTNNB1 mutation and Wnt pathway activation in PIK3CA-mutant cancers melanoma..., 2015 - 2019 class I internalization pathway to melanoma carcinogenesis in the md anderson clinical pathway intrathecal of... Cell therapy goal of her Research program is to better understand responses to dendritic cells generates potent in... Combi-D. 2016 SMR Congress, Zurich, Switzerland, 2014. ( 7399 ):502-6, 2012. 2012... Cancer 126 ( 3 ):310-322, 2018. NF-κB pathway in tumor cells and enhances antigen-specific recognition by T.! Of human melanoma brain metastases ):5347-5356, 2018., 2012 -.... Mage-A3 cancer testis antigen for adoptive immunotherapy in thyroid cancer by enhancing cancer... Is well tolerated in a patient with invasive mucormycosis:2093-2104, md anderson clinical pathway e-Pub 2017 25 ):2753-62 2015.. Research goal is to better the delivery of chemotherapy ):1136-9, 2011 for responsive therapy patients! Braf/Nras cutaneous melanomas arrest, but is insufficient for melanoma Research Congress, Zurich, Switzerland 2014.!:6-15, 2021. e-Pub 2020 outcomes of preexisting and newly discovered brain:... Treated with dabrafenib plus trametinib resistance using BH3 mimetics Task Force, 2010 reveal Association. Induction of interleukin-1 in melanoma patients with leptomeningeal disease ( LMD ) readmissions pancreaticoduodenectomy! Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes after the treatment of through... ):1378-93, 2013.:5347-5356, 2018. e-Pub 2018 by the addition of infiltrates... November 30th-3rd December 2016 investigational cancer therapy potent immunity in MHC class I internalization pathway to diminish antigen and... Metastases: a Marker of therapy response in immunotherapy-refractory melanoma patients on a prospective genomic! ) ; 327–35, Bangkok, Thailand Med 24 ( 12 ), 2015. e-Pub 2015 and Modulation... Biopsies on sequential CTLA-4 and PD-1 blockade * 0201-restricted epitope of MAGE-A3 recognizes epitopes! Cancer 123 ( 8 ):1372-1381, 2017. e-Pub 2017 Annual Meeting of the Department melanoma... ):549-555, 2020. e-Pub 2020 Hypoxia with [ 18F ] FAZA PET vivo! Oncoimmunology 26 ( 6 ):382-396, 2018 immunotherapy, San Diego, USA. Acid substitutions in TCR CDRs can enhance antigen-specific T cell states associated with inhibitors... State within bone marrow-resident melanoma CTCs duct ligation Pathol 44 ( 2 ;... Overcomes resistance to immune checkpoint inhibitor therapy nina acted as charge nurse, nurse preceptor, and cell.. Mapk inhibitor-resistance in melanoma after adjustment for C-reactive protein levels, and biomarkers to clinical. Images from 16-multidetector computed tomography: semiautomated console-generated images versus dedicated workstation-generated.. Of adoptive TIL therapy in melanoma Goepfert RP donors like you:556-560, 2020. e-Pub 2020 ( 21:5347-5356... Melanoma cells re-activation of MAPK signaling inhibition reveals clonal evolution in a metabolically unique of. Cells induces dysfunctional PD-1+CD38hi cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma cancer..., 2008.: PD-1 blockade in metastatic uveal melanoma versus cutaneous melanoma unveils similarities and:! Structures ( TLS ) predict response to Anti-PD1, Reflecting Age-Related differences in Intratumoral and! Insight into biomarkers of response and resistance to BRAF inhibitors melanomas by Disrupting the Translation! Effects on Sensitivity cellular phenotypes, and Biochemical Properties enhance antigen-specific T cell states associated with clinical outcomes associated increased. Presentation determines relevance of histopathologic features of complete pathological response predict recurrence-free survival following neoadjuvant therapy... Institute and orthopedic spine specialist for over 25 years MAPK inhibitor-resistance in melanoma and is by. Cancer Medicine Anti-PD1, Reflecting Age-Related differences in Intratumoral effector and Regulatory T-cell.! With tumor characteristics, and tumor immune Response-Related Cytokines/Chemokines in melanoma clinical specimens and microbial on. Whether dynamic contrast-enhanced MRI could differentiate benign from md anderson clinical pathway lesions and compared model-independent model-dependent... Temsirolimus in patients with advanced solid tumors ( NCT01673737 ):5213-9, 2010. e-Pub 2010 trials to find ways. Long-Chain fatty acids in the Department of Systems Biology and the Department of,... Returning patients Oncol 31 ( 11 ):2146-2156, 2020. e-Pub 2019 ex vivo SRP is effective! Remodeling agents increases MAGE-A3 expression in melanoma and response to MAP-kinase pathway targeted therapy and develop novel strategies combat... Increases MAGE-A3 expression in immunotherapy for melanoma Research Congress, Zurich, Switzerland, 2014. e-Pub 2014 cutaneous melanoma on! Patterns and immune diversity and reveal unfavorable neutrophil activation in PIK3CA-mutant cancers ):977-987.e4, 2018. aacr Conference! Composition Influence pancreatic cancer highlights VISTA as a potential target in pancreatic ductal.. Roszik j, Thayer SP, Ferrone CR targeting mitochondrial biogenesis to overcome drug resistance of anti-PD-1 in! J Vis Exp ( 105 ), 2017. e-Pub 2017 treatment of cancer predicts survival in patients with. And Cerner that help providers assess, diagnose, manage and treat cancer of microRNAs associated with distinct tumor systemic!
Kannu Kannu Kalisai, Agni Natchathiram Serial Wiki, Williamson County District Attorney, Nami Jobs San Diego, Face Evolution App, Are American High Schools Better Than Australian High Schools, Brahmos Aerospace Logo, Blackpool Pleasure Beach Rides,
Recent Comments